Weglim-M1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and increases peripheral insulin sensitivity, contributing to better glucose utilization. The synergistic action of these two agents addresses both insulin deficiency and insulin resistance, making Weglim-M1 effective in controlling blood glucose levels in patients inadequately managed by diet and exercise alone. This prolonged-release formulation ensures a steady release of active ingredients, promoting better compliance and minimizing gastrointestinal side effects commonly associated with metformin. Weglim-M1 is typically administered once daily with meals to optimize absorption and reduce hypoglycemia risk. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. Weglim-M1 should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular medical supervision.